September 2018

New Product - Inovelon

Rufinamide (Inovelon) is a carboxamide derivative antiepileptic that modulates the activity of sodium channels, prolonging their inactive state. Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older. Treatment with Inovelon should be initiated by a physician specialised in paediatrics or neurology with experience in the treatment of epilepsy. Inovelon is contraindicated with hypersensitivity to triazole derivatives. Inovelon tablets contain rufinamide 200 mg or 400 mg and are available in packs of 60.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629